Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

Authors: Britt Kveiborg, Thomas S Hermann, Atheline Major-Pedersen, Buris Christiansen, Christian Rask-Madsen, Jakob Raunsø, Lars Køber, Christian Torp-Pedersen, Helena Dominguez

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Aim

Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment compared to carvedilol on indices of insulin resistance. The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes.

Method

24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or 50 mg carvedilol daily. Endothelium-dependent vasodilation was assessed by using venous occlusion plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin. Insulin-stimulated endothelial function was assessed after co-infusion of insulin for sixty minutes. Vaso-reactivity studies were done before and after the two-month treatment period.

Results

Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage change in forearm blood-flow was 60.19% ± 17.89 (at the highest serotonin dosages) before treatment and -33.80% ± 23.38 after treatment (p = 0.007). Treatment with carvedilol did not change insulin-stimulated endothelial function. Endothelium-dependent vasodilation without insulin was not changed in either of the two treatment groups.

Conclusion

This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes.

Trial registration

Current Controlled Trials NCT00497003
Appendix
Available only for authorised users
Literature
1.
go back to reference Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.
2.
go back to reference Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama. 2004, 292: 2227-2236. 10.1001/jama.292.18.2227.CrossRefPubMed Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama. 2004, 292: 2227-2236. 10.1001/jama.292.18.2227.CrossRefPubMed
3.
go back to reference Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362: 7-13. 10.1016/S0140-6736(03)13800-7.CrossRefPubMed Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362: 7-13. 10.1016/S0140-6736(03)13800-7.CrossRefPubMed
4.
go back to reference Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A: Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007, 93: 968-973. 10.1136/hrt.2006.092379.PubMedCentralCrossRefPubMed Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A: Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007, 93: 968-973. 10.1136/hrt.2006.092379.PubMedCentralCrossRefPubMed
5.
go back to reference Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed
6.
go back to reference Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001, 104: 2673-2678. 10.1161/hc4601.099485.CrossRefPubMed Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001, 104: 2673-2678. 10.1161/hc4601.099485.CrossRefPubMed
7.
go back to reference Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996, 97: 2601-2610. 10.1172/JCI118709.PubMedCentralCrossRefPubMed Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996, 97: 2601-2610. 10.1172/JCI118709.PubMedCentralCrossRefPubMed
8.
go back to reference Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001, 50: 2611-2618. 10.2337/diabetes.50.11.2611.CrossRefPubMed Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001, 50: 2611-2618. 10.2337/diabetes.50.11.2611.CrossRefPubMed
9.
go back to reference Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 1995, 38: 555-564. 10.1007/BF00400724.CrossRefPubMed Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 1995, 38: 555-564. 10.1007/BF00400724.CrossRefPubMed
10.
go back to reference Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000, 20: 545-550.CrossRefPubMed Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000, 20: 545-550.CrossRefPubMed
11.
go back to reference Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004, 27 (Suppl 1): S5-S10. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004, 27 (Suppl 1): S5-S10.
12.
go back to reference Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, Nielsen DB, Hansen KW, Hawkins M, Kober L, Torp-Pedersen C: Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006, 91: 1001-1008. 10.1210/jc.2005-1231.CrossRefPubMed Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, Nielsen DB, Hansen KW, Hawkins M, Kober L, Torp-Pedersen C: Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006, 91: 1001-1008. 10.1210/jc.2005-1231.CrossRefPubMed
13.
go back to reference Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C: Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005, 42: 517-525. 10.1159/000088261.CrossRefPubMed Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C: Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005, 42: 517-525. 10.1159/000088261.CrossRefPubMed
14.
go back to reference Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V: Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications. 2008, 22: 303-308. 10.1016/j.jdiacomp.2007.05.003.PubMedCentralCrossRefPubMed Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V: Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications. 2008, 22: 303-308. 10.1016/j.jdiacomp.2007.05.003.PubMedCentralCrossRefPubMed
15.
go back to reference Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989, 2: 997-1000. 10.1016/S0140-6736(89)91013-1.CrossRefPubMed Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989, 2: 997-1000. 10.1016/S0140-6736(89)91013-1.CrossRefPubMed
16.
go back to reference Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000, 20: 538-544.CrossRefPubMed Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000, 20: 538-544.CrossRefPubMed
17.
go back to reference Verma S, Arikawa E, Yao L, Laher I, McNeill JH: Insulin-induced vasodilation is dependent on tetrahydrobiopterin synthesis. Metabolism. 1998, 47: 1037-1039. 10.1016/S0026-0495(98)90273-6.CrossRefPubMed Verma S, Arikawa E, Yao L, Laher I, McNeill JH: Insulin-induced vasodilation is dependent on tetrahydrobiopterin synthesis. Metabolism. 1998, 47: 1037-1039. 10.1016/S0026-0495(98)90273-6.CrossRefPubMed
18.
go back to reference Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996, 14: 489-494. 10.1097/00004872-199604000-00012.PubMed Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996, 14: 489-494. 10.1097/00004872-199604000-00012.PubMed
19.
go back to reference Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997, 126: 955-959.CrossRefPubMed Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997, 126: 955-959.CrossRefPubMed
20.
go back to reference Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Bmj. 1989, 298: 1152-1157. 10.1136/bmj.298.6681.1152.PubMedCentralCrossRefPubMed Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Bmj. 1989, 298: 1152-1157. 10.1136/bmj.298.6681.1152.PubMedCentralCrossRefPubMed
21.
go back to reference Pischon T, Sharma AM: Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev. 2001, 2: 275-280. 10.1046/j.1467-789X.2001.00044.x.CrossRefPubMed Pischon T, Sharma AM: Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev. 2001, 2: 275-280. 10.1046/j.1467-789X.2001.00044.x.CrossRefPubMed
22.
go back to reference Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Stumvoll M, Weyer C, Tataranni PA: Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes. 2002, 51: 2964-2967. 10.2337/diabetes.51.10.2964.CrossRefPubMed Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Stumvoll M, Weyer C, Tataranni PA: Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes. 2002, 51: 2964-2967. 10.2337/diabetes.51.10.2964.CrossRefPubMed
23.
go back to reference Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005, 54: 534-539. 10.2337/diabetes.54.2.534.CrossRefPubMed Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005, 54: 534-539. 10.2337/diabetes.54.2.534.CrossRefPubMed
24.
go back to reference Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006, 24: 591-596. 10.1097/01.hjh.0000209993.26057.de.CrossRefPubMed Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006, 24: 591-596. 10.1097/01.hjh.0000209993.26057.de.CrossRefPubMed
25.
go back to reference von zur Muhlen B, Millgard J, Lind L: Divergent effects of different beta-blocking agents on endothelium-dependent vasodilatation in the human forearm. Blood Press. 2000, 9: 287-292. 10.1080/080370500448687.CrossRefPubMed von zur Muhlen B, Millgard J, Lind L: Divergent effects of different beta-blocking agents on endothelium-dependent vasodilatation in the human forearm. Blood Press. 2000, 9: 287-292. 10.1080/080370500448687.CrossRefPubMed
26.
go back to reference von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001, 19: 1813-1818. 10.1097/00004872-200110000-00015.CrossRefPubMed von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001, 19: 1813-1818. 10.1097/00004872-200110000-00015.CrossRefPubMed
27.
go back to reference Hess OM, Bortone A, Gaglione A, Nonogi H, Grimm J, Krayenbuehl HP: Effect of intracoronary and intravenous propranolol on human coronary arteries. Eur Heart J. 1989, 10 (Suppl F): 153-158.CrossRefPubMed Hess OM, Bortone A, Gaglione A, Nonogi H, Grimm J, Krayenbuehl HP: Effect of intracoronary and intravenous propranolol on human coronary arteries. Eur Heart J. 1989, 10 (Suppl F): 153-158.CrossRefPubMed
28.
go back to reference Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP: Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation. 1990, 81: 1225-1235.CrossRefPubMed Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP: Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation. 1990, 81: 1225-1235.CrossRefPubMed
29.
go back to reference Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M: Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000, 140: 753-759. 10.1067/mhj.2000.110093.CrossRefPubMed Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M: Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000, 140: 753-759. 10.1067/mhj.2000.110093.CrossRefPubMed
30.
go back to reference Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992, 263: 92-98.PubMed Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992, 263: 92-98.PubMed
31.
go back to reference Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003, 107: 2747-2752. 10.1161/01.CIR.0000066912.58385.DE.CrossRefPubMed Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003, 107: 2747-2752. 10.1161/01.CIR.0000066912.58385.DE.CrossRefPubMed
32.
go back to reference Afonso RA, Patarrao RS, Macedo MP, Carmo MM: Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006, 19: 419-425. 10.1016/j.amjhyper.2005.11.011.CrossRefPubMed Afonso RA, Patarrao RS, Macedo MP, Carmo MM: Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006, 19: 419-425. 10.1016/j.amjhyper.2005.11.011.CrossRefPubMed
33.
go back to reference Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F: Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998, 21: 631-636. 10.2337/diacare.21.4.631.CrossRefPubMed Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F: Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998, 21: 631-636. 10.2337/diacare.21.4.631.CrossRefPubMed
34.
go back to reference Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996, 93: 1107-1113.CrossRefPubMed Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996, 93: 1107-1113.CrossRefPubMed
35.
go back to reference Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007, 20: 777-783. 10.1016/j.amjhyper.2007.01.019.CrossRefPubMed Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007, 20: 777-783. 10.1016/j.amjhyper.2007.01.019.CrossRefPubMed
36.
go back to reference Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications. 2001, 15: 203-210. 10.1016/S1056-8727(01)00143-X.CrossRefPubMed Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications. 2001, 15: 203-210. 10.1016/S1056-8727(01)00143-X.CrossRefPubMed
Metadata
Title
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study
Authors
Britt Kveiborg
Thomas S Hermann
Atheline Major-Pedersen
Buris Christiansen
Christian Rask-Madsen
Jakob Raunsø
Lars Køber
Christian Torp-Pedersen
Helena Dominguez
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-21

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue